Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

Neurology
W G Tatton, R M E Chalmers-Redman

Abstract

(-)-Deprenyl has been used to irreversibly inhibit monoamine oxidase B (MAO-B) in Parkinson's disease (PD) and Alzheimer's disease (AD) as a possible means of improving dopaminergic neurotransmission or of reducing neuronal necrosis caused by oxidative radical damage. Recent research in tissue culture and animal models has shown that (-)-deprenyl can reduce neuronal apoptosis caused by a variety of agents, in a variety of neuronal subtypes through a mechanism(s) that does not require MAO-B inhibition. Studies using general P450 blockers have shown that one of the principal metabolites of (-)-deprenyl, (-)-desmethyldeprenyl, mediates the antiapoptotic action. Other research has shown that (-)-deprenyl can induce altered expression of a number of genes in preapoptotic neurons both in vitro and in vivo, including the genes for superoxide dismutase (SOD) 1 and 2, BCL-2 and BCL-XL, nitric oxide synthase, c-JUN, and nicotinamide adenine dinucleotide dehydrogenase. Antiapoptosis by (-)-deprenyl is associated with a prevention of a progressive reduction of mitochondrial membrane potential in preapoptotic neurons, which has been shown to occur early in apoptosis and is likely an initiating factor. The above changes in gene expression ap...Continue Reading

Citations

Jun 17, 2005·Journal of Neural Transmission·K TakahataA Akaike
Aug 23, 2011·In Vitro Cellular & Developmental Biology. Animal·Shabnam BakhshalizadehMojtaba Saedi
Oct 18, 2003·Biochemical Pharmacology·Umberto De MarchiAntonio Toninello
Dec 25, 2002·European Journal of Pharmacology·Kazue TakahataAkinori Akaike
Sep 21, 2000·Mechanisms of Ageing and Development·W MaruyamaM Naoi
Jun 5, 2002·Mechanisms of Ageing and Development·Srinivasan ThyagaRajan, David L Felten
Feb 3, 2000·Mechanisms of Ageing and Development·W Maruyama, M Naoi
Feb 11, 1999·Pharmacology, Biochemistry, and Behavior·D L Gelowitz, I A Paterson
Dec 31, 2003·Neurotoxicology·Kálmán Magyar, Béla Szende
Mar 27, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Peter C Waldmeier
Aug 8, 2001·Parkinsonism & Related Disorders·M Naoi, W Maruyama
Jul 2, 2008·Parkinsonism & Related Disorders·P FoleyP Riederer
Mar 1, 2006·Proceedings of the National Academy of Sciences of the United States of America·Makoto R HaraSolomon H Snyder
Jun 28, 2003·Neurotoxicity Research·Emilia Mabel GattoFederico E Micheli
Jun 28, 2003·Neurotoxicity Research·Richard M. Kostrzewa, Juan Segura-Aguilar
Oct 30, 2004·Journal of Toxicology and Environmental Health. Part a·Sang Geon KimJeong Weon Park
Apr 15, 1999·Annual Review of Neuroscience·C W Olanow, W G Tatton
Apr 15, 1999·Annual Review of Neuroscience·J C ShihM J Ridd
Jun 3, 2010·Clinical Interventions in Aging·Julie Leegwater-Kim, Elena Bortan
Aug 21, 2010·Neurochemical Research·K MagyarE Szöko
Dec 29, 2015·Trends in Pharmacological Sciences·Tomohiro Nakamura, Stuart A Lipton
Jun 24, 2009·Optometry : Journal of the American Optometric Association·Kelly ShintaniAndrew S Gurwood
Dec 27, 2006·Journal of Ethnopharmacology·Amar JyotiDeepak Sharma

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis